|
|
 Previous Article | Table of Contents | Next Article 
HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a
previously unrecognized form of acute leukemia potentially misdiagnosed as
French-American-British acute myeloid leukemia-M3 [see comments]
AA Scott, DR Head, KJ Kopecky, FR Appelbaum, KS Theil, MR Grever, IM Chen, MH Whittaker, BB Griffith and JD Licht
University of New Mexico (UNM) School of Medicine, Department of Pathology,
Albuquerque.
We have identified and characterized a previously unrecognized form of
acute leukemia that shares features of both myeloid and natural killer (NK)
cells. From a consecutive series of 350 cases of adult de novo acute
myeloid leukemia (AML), we identified 20 cases (6%) with a unique
immunophenotype: CD33+, CD56+, CD11a+, CD13lo, CD15lo, CD34+/-, HLA-DR- ,
CD16-. Multicolor flow cytometric assays confirmed the coexpression of
myeloid (CD33, CD13, CD15) and NK cell-associated (CD56) antigens in each
case, whereas reverse transcription polymerase chain reaction (RT- PCR)
assays confirmed the identity of CD56 (neural cell adhesion molecule) in
leukemic blasts. Although two cases expressed CD4, no case expressed CD2,
CD3, or CD8 and no case showed clonal rearrangement of genes encoding the
T-cell receptor (TCR beta, gamma, delta). Leukemic blasts in the majority
of cases shared unique morphologic features (deeply invaginated nuclear
membranes, scant cytoplasm with fine azurophilic granularity, and finely
granular Sudan black B and myeloperoxidase cytochemical reactivity) that
were remarkably similar to those of acute promyelocytic leukemia (APL);
particularly the microgranular variant (FAB AML-M3v). However, all 20 cases
lacked the t(15;17) and 17 cases tested lacked the promyelocytic/retinoic
acid receptor alpha (RAR alpha) fusion transcript in RT-PCR assays; 12
cases had 46,XX or 46,XY karyotypes, whereas 2 cases had abnormalities of
chromosome 17q: 1 with del(17)(q25) and the other with t(11;17)(q23;q21)
and the promyelocytic leukemia zinc finger/RAR alpha fusion transcript. All
cases tested (6/20), including the case with t(11;17), failed to
differentiate in vitro in response to all-trans retinoic acid (ATRA),
suggesting that these cases may account for some APLs that have not shown a
clinical response to ATRA. Four of 6 cases tested showed functional NK
cell-mediated cytotoxicity, suggesting a relationship between these unique
CD33+, CD56+, CD16- acute leukemias and normal CD56+, CD16- NK precursor
cells. Using a combination of panning and multiparameter flow cytometric
sorting, we identified a normal CD56+, CD33+, CD16- counterpart cell at a
frequency of 1% to 2% in the peripheral blood of healthy individuals. Our
studies suggest that this form of acute leukemia may arise from
transformation of a precursor cell common to both the myeloid and NK cell
lineages; thus we propose the designation myeloid/NK acute leukemia.
Recognition of this new leukemic entity will be important in distinguishing
these ATRA- nonresponsive cases from ATRA-responsive true APL.
Volume 84,
Issue 1,
pp. 244-255,
07/01/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
W. Chen, G. Z. Rassidakis, J. Li, M. Routbort, D. Jones, H. Kantarjian, L. J. Medeiros, and C. E. Bueso-Ramos
High frequency of NPM1 gene mutations in acute myeloid leukemia with prominent nuclear invaginations ("cuplike" nuclei).
Blood,
September 1, 2006;
108(5):
1783 - 1784.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Sconocchia, H. Fujiwara, K. Rezvani, K. Keyvanfar, F. El Ouriaghli, M. Grube, J. Melenhorst, N. Hensel, and A. J. Barrett
G-CSF-mobilized CD34+ cells cultured in interleukin-2 and stem cell factor generate a phenotypically novel monocyte
J. Leukoc. Biol.,
December 1, 2004;
76(6):
1214 - 1219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Meech, L. McGavran, L. F. Odom, X. Liang, L. Meltesen, J. Gump, Q. Wei, S. Carlsen, and S. P. Hunger
Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4-anaplastic lymphoma kinase gene fusion
Blood,
August 15, 2001;
98(4):
1209 - 1216.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Chaperot, N. Bendriss, O. Manches, R. Gressin, M. Maynadie, F. Trimoreau, H. Orfeuvre, B. Corront, J. Feuillard, J.-J. Sotto, et al.
Identification of a leukemic counterpart of the plasmacytoid dendritic cells
Blood,
May 15, 2001;
97(10):
3210 - 3217.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Greer, M. C. Kinney, and T. P. Loughran Jr.
T Cell and NK Cell Lymphoproliferative Disorders
Hematology,
January 1, 2001;
2001(1):
259 - 281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Sainty, V. Liso, A. Cantu-Rajnoldi, D. Head, M.-J. Mozziconacci, C. Arnoulet, L. Benattar, S. Fenu, M. Mancini, E. Duchayne, et al.
A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements
Blood,
August 15, 2000;
96(4):
1287 - 1296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Grimwade, A. Biondi, M.-J. Mozziconacci, A. Hagemeijer, R. Berger, M. Neat, K. Howe, N. Dastugue, J. Jansen, I. Radford-Weiss, et al.
Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party
Blood,
August 15, 2000;
96(4):
1297 - 1308.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Ferrara, F. Morabito, B. Martino, G. Specchia, V. Liso, F. Nobile, P. Boccuni, R. Di Noto, F. Pane, M. Annunziata, et al.
CD56 Expression Is an Indicator of Poor Clinical Outcome in Patients With Acute Promyelocytic Leukemia Treated With Simultaneous All-Trans-Retinoic Acid and Chemotherapy
J. Clin. Oncol.,
March 13, 2000;
18(6):
1295 - 1300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. K. Murray, E. Estey, E. Paietta, R. S. Howard, W. J. Edenfield, S. Pierce, K. P. Mann, C. Bolan, and J. C. Byrd
CD56 Expression in Acute Promyelocytic Leukemia: A Possible Indicator of Poor Treatment Outcome?
J. Clin. Oncol.,
January 1, 1999;
17(1):
293 - 293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Viswanatha, I.-M. Chen, P. P. Liu, M. L. Slovak, C. Rankin, D. R. Head, and C. L. Willman
Characterization and Use of an Antibody Detecting the CBFbeta -SMMHC Fusion Protein in inv(16)/t(16;16)-Associated Acute Myeloid Leukemias
Blood,
March 15, 1998;
91(6):
1882 - 1890.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Jennings and K. A. Foon
Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy
Blood,
October 15, 1997;
90(8):
2863 - 2892.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Suzuki, K. Yamamoto, M. Seto, Y. Kagami, M. Ogura, Y. Yatabe, T. Suchi, Y. Kodera, Y. Morishima, T. Takahashi, et al.
CD7+ and CD56+ Myeloid/Natural Killer Cell Precursor Acute Leukemia: A Distinct Hematolymphoid Disease Entity
Blood,
September 15, 1997;
90(6):
2417 - 2428.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Mandelli, D. Diverio, G. Avvisati, A. Luciano, T. Barbui, C. Bernasconi, G. Broccia, R. Cerri, M. Falda, G. Fioritoni, et al.
Molecular Remission in PML/RARalpha -Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy
Blood,
August 1, 1997;
90(3):
1014 - 1021.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K.C. Chan, V.C. Sin, K.F. Wong, C.S. Ng, W. Y.W. Tsang, C.H. Chan, M.M.C. Cheung, and W.H. Lau
Nonnasal Lymphoma Expressing the Natural Killer Cell Marker CD56: A Clinicopathologic Study of 49 Cases of an Uncommon Aggressive Neoplasm
Blood,
June 15, 1997;
89(12):
4501 - 4513.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Drenou, T. Lamy, L. Amiot, O. Fardel, S. Caulet-Maugendre, M. Sasportes, J. Diebold, P.-Y. Le Prise, and R. Fauchet
CD3-CD56+ Non-Hodgkin's Lymphomas With an Aggressive Behavior Related to Multidrug Resistance
Blood,
April 15, 1997;
89(8):
2966 - 2974.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
